Bambusa Therapeutics, Inc.

Bambusa Therapeutics, Inc. publicly filed a registration statement on Form S-1 on Oct 9, 2026 for a proposed initial public offering on Nasdaq Global Select under the ticker BBTX, and has not yet priced. Underwriters named in the filing: BofA Securities, Evercore ISI, UBS and Cantor.

Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing long-acting bispecific antibodies for immunology and inflammation. Its candidates combine validated biologic pathways in a single molecule designed for high-concentration subcutaneous delivery, using third-party antibody engineering.

Status

Filed, not priced

Ticker

BBTX

Exchange

Nasdaq Global Select

First filed

Oct 9, 2026

Latest amendment

Oct 9, 2026

Underwriters

BofA Securities, Evercore ISI, UBS and Cantor

Sector

Biotech & pharma

Country / state

MA